Mike Youle

Q: What Schools Are Affiliated With Mike Youle

Mike Youle is affiliated with the following schools: University of York, University of Sheffield, University College London, Imperial College London, University of Toronto

Mike Youle's AcademicInfluence.com Rankings

Mike Youle

Philosophy

#11375

World Rank

#15660

Historical Rank

Logic

#8194

World Rank

#10212

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Mike Youle's Degrees

PhD HIV Medicine Imperial College London

Why Is Mike Youle Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Michael Simon Youle is a British doctor and clinical researcher specializing in HIV treatment. He publicised the concept of pre-exposure prophylaxis for HIV and has studied the health economics of HIV therapy. In 1995, he was listed as one of 40 influential gay men by The Independent.

(See a Problem?)

Mike Youle's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 (2005) (505)
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (2012) (387)
Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir (2006) (362)
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials (2010) (311)
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. (1999) (305)
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre (2001) (272)
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy (2004) (229)
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) (2014) (195)
European guidelines for the clinical management and treatment of HIV-infected adults in Europe. (2003) (195)
Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing (2004) (185)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting (2001) (184)
Anti‐herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection (1996) (174)
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. (2004) (166)
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. (1989) (145)
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. (2003) (131)
Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment (2001) (120)
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. (1998) (115)
Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease (1999) (108)
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy (2004) (108)
A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection (1998) (104)
Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population (2000) (101)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. (2001) (101)
Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. (1998) (101)
Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure (2014) (98)
A double‐blind, parallel‐group, placebo‐controlled, multicentre study of acetyl l‐carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV‐1 infection (2007) (98)
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy (2003) (96)
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers (2006) (94)
Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. (1988) (94)
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. (2007) (92)
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. (2006) (90)
Health-Related Quality of Life in Individuals Infected with HIV in the Era of HAART (2001) (86)
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. (1999) (84)
Effects of high‐dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double‐blind, placebo‐controlled study (1994) (84)
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study (2005) (83)
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. (2007) (83)
Systemic acetyl-l-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma (2002) (83)
A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial (2005) (79)
The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. (1998) (77)
Effect of painless rectal distension on gastrointestinal transit of solid meal (1984) (76)
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population (2009) (75)
British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2003) (68)
Survival after diagnosis of AIDS: a prospective observational study of 2625 patients (1997) (65)
Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency Virus (1998) (64)
Thalidomide is distributed into human semen after oral dosing. (2001) (62)
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. (2001) (62)
Itraconazole cyclodextrin solution--effective treatment for HIV-related candidosis unresponsive to other azole therapy. (1994) (59)
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals (2011) (58)
The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. (1999) (57)
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study (2017) (55)
Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study (1999) (54)
Kaposi's Sarcoma-Associated Herpesvirus Cytotoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes (2003) (54)
Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial (2016) (53)
Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender * (2007) (53)
Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. (2007) (51)
Pre-Exposure Chemoprophylaxis (PREP) as an HIV Prevention Strategy (2003) (51)
Staging system for clinical AIDS patients (1995) (51)
HUMAN IMMUNODEFICIENCY VIRUS REBOUND AFTER SUPPRESSION TO <400 C/ML DURING INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY REGIMENS, ACCORDING TO PRIOR NUCLEOSIDE EXPERIENCE AND DURATION OF SUPPRESSION (2002) (51)
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? (2003) (50)
Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. (1994) (49)
No association between HIV disease and its treatment and thyroid function (2007) (49)
The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. (1990) (48)
Stability of antiretroviral regimens in patients with viral suppression (2008) (48)
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? (2002) (47)
SEVERE HYPOCALCAEMIA IN AIDS PATIENTS TREATED WITH FOSCARNET AND PENTAMIDINE (1988) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013 (2010) (44)
Assessing the cost‐effectiveness of HAART for adults with HIV in England (2001) (44)
The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996–2008 (2011) (44)
Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. (2000) (43)
Rheumatological lesions in individuals with human immunodeficiency virus infection. (1989) (42)
Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development (2001) (41)
Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection (1997) (41)
Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens (2000) (40)
A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial (2005) (39)
An audit of antiretroviral treatment use in HIV‐infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use (2003) (39)
A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. (1997) (37)
Long-Term Effect of Acetyl-L-Carnitine for Antiretroviral Toxic Neuropathy (2005) (36)
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial (2021) (34)
Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors (1999) (34)
Acetyl-L-Carnitine in HIV-Associated Antiretroviral Toxic Neuropathy (2007) (32)
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. (2003) (32)
Megestrol Acetate Vs Cyproheptadine in the Treatment of Weight Loss Associated with HIV Infection (1992) (31)
Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults (2012) (30)
MEASURING THE EFFECT OF CLINICAL GUIDELINES ON PATIENT OUTCOMES (2000) (28)
Participation in clinical studies among patients infected with HIV‐1 in a single treatment centre over 12 years (2000) (28)
Treatment Outcome and Cost-Effectiveness of Different Highly Active Antiretroviral Therapy Regimens in the Uk (1996–2002) (2008) (27)
A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. (1998) (27)
Thalidomide in hyperalgic pharyngeal ulceration of AIDS (1990) (27)
Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations (2006) (26)
Lower Healthcare Costs Associated with the Use of a Single-Pill ARV Regimen in the UK, 2004–2008 (2012) (25)
Factors associated with viral rebound among highly treatment‐experienced HIV‐positive patients who have achieved viral suppression (2009) (25)
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy. (2002) (24)
Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. (1999) (24)
Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex (1991) (24)
A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study (2006) (24)
Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients: The Role of Gender (2007) (23)
Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. (1990) (23)
Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease (2009) (23)
The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study. (1989) (23)
Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom (2014) (23)
Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. (2002) (23)
Anti-CD4 autoantibodies and screening for anti-idiotypic antibodies to anti-CD4 monoclonal antibodies in HIV-seropositive people. (1990) (23)
Restriction of sensitivity of HIV-1-antigen ELISA by serum anti-core antibodies. (1988) (22)
Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma (1996) (22)
The Influence of HIV Infection and Antiretroviral Therapy on the Mitochondrial Membrane Potential of Peripheral Mononuclear Cells (2007) (22)
HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice. (1995) (21)
Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration – a comprehensive meeting report (2017) (21)
Diclazuril in the treatment of severe cryptosporidial diarrhoea in AIDS patients. (1990) (21)
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
Use of terbinafine in HIV‐positive subjects: pilot studies in onychomycosis and oral candidiasis (1996) (20)
A randomized, double‐blind, placebo‐controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection (2001) (20)
Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. (2003) (19)
Pharmacokinetics and Absolute Bioavailability of Oral Foscarnet in Human Immunodeficiency Virus-Seropositive Patients (1998) (18)
The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens (2005) (16)
Assessing the cost-effectiveness of highly active antiretroviral therapy for adults with HIV in England (2001) (16)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study (2013) (15)
British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2001) (15)
Clinical relevance of the plasma load of cytomegalovirus in patients infected with HIV—A survival analysis (2014) (15)
Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. (1998) (15)
Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV (2012) (15)
The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High‐Density Lipoprotein Cholesterol in HIV‐Infected Patients Receiving Efavirenz (2009) (14)
A Prospective, Double Blind, Randomised, Placebo Controlled Trial Evaluating Acetyl-L-Carnitine (ALCAR) for the Prevention of Distal Symmetric Polyneuropathy in HIV Infected Individuals (2010) (14)
The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom (2000) (14)
Naively changing HAART (2002) (14)
Foscarnet-induced changes in plasma concentrations of total and ionized calcium and magnesium in HIV-positive patients. (1996) (13)
The prevalence of antiretroviral drug resistance in patients with low-level detectable viraemia while on HAART (2006) (13)
Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic (2009) (13)
Human chorionic gonadotropin for AIDS-related Kaposi's sarcoma (1995) (13)
Salvage treatment in HIV disease (2001) (13)
Changing treatment patterns among patients with HIV: Royal Free Hospital 1987–97 (1999) (13)
Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006 (2011) (13)
Development and application of a new measure of engagement in out‐patient HIV care (2016) (13)
Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. (2000) (12)
Health economics in HIV disease. A review of the European literature. (1999) (12)
Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. (2020) (11)
The use of computational models to predict response to HIV therapy for clinical cases in Romania. (2012) (10)
Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. (1994) (10)
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study. (1990) (10)
Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study (2016) (9)
Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update) (2014) (9)
Amyl Nitrite Induced Acute Haemolytic Anaemia in HIV-Antibody Positive Man (2000) (9)
Is interruption of HIV therapy always harmful? (2000) (8)
Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients. (2008) (8)
Histoplasmosis in a UK patient treated with itraconazole. (1990) (8)
Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy (1997) (8)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation (2015) (8)
Health Economics in HIV Disease (2012) (8)
HIV-Associated Antiretroviral Toxic Neuropathy (ATN): A Review of Recent Advances in Pathophysiology and Treatment (2005) (8)
Renal excretion and pharmacokinetics of foscarnet in HIV sero-positive patients: effect of probenecid pretreatment. (1997) (7)
The safety of intravenous chemotherapy and zidovudine when treating epidemic Kaposi's sarcoma. (1989) (7)
Diagnosis, treatment and outcome of pneumonia in the acquired immune deficiency syndrome. (1989) (7)
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection (2003) (7)
A Prospective Evaluation of the Cost Effectiveness of Adding Lamivudine to Zidovudine-Containing Antiretroviral Treatment Regimens in HIV Infection (2012) (7)
An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy (2008) (7)
An achievable goal. (1998) (6)
Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy (2017) (6)
A step ahead on the HIV collaboratory. (2009) (6)
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV (2019) (6)
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance (2018) (6)
Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives? (2009) (6)
Effect of management strategies and clinical status on costs of care for advanced HIV. (2014) (5)
Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing. (2002) (5)
Modelling the cost of lamivudine/zidovudine combination therapy in HIV infection (1997) (5)
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals (2008) (5)
Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium (2020) (4)
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals (2004) (4)
CLINICAL STAGING SYSTEM FOR AIDS PATIENTS - REPLY (1995) (4)
The effect of HIV status on the frequency and severity of acute respiratory illness (2020) (4)
A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada (2017) (3)
Resolution of azole-resistant oesophageal candidiasis in an AIDS patient after treatment with caspofungin. (2003) (3)
Didanosine once daily: an overview. (1998) (3)
Influence of liver fibrosis stage on nevirapine plasma concentration in HIV-infected patients with chronic hepatitis C virus (2014) (3)
Engagement in care among youth living with parenterally-acquired HIV infection in Romania (2019) (3)
Epidemiological characteristics and access to end-stage liver disease care for HIV-positive patients with HCV and/or HBV coinfections in Central/Eastern European and neighboring countries – data from the ECEE network (2019) (3)
Strategies of HIV management—when to start (2002) (3)
Clinical, immunological, and virological effects of sodium fusidate in patients with AIDS or AIDS-related complex (ARC): an open study. (1989) (3)
Economic implication of HIV-1 resistance testing in overall clinical care (2004) (3)
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies. (2007) (3)
Health economics. Perfect combination. (1999) (3)
Pharmacokinetics of Acetyl-L-Carnitine Given in Single or Multiple Doses to HIV-1 Infected Patients with Toxic Peripheral Polyneuropathy (2008) (2)
Cytotoxic and humoral immune responses to HIV-1 p17 synthetic peptide HGP-30 in human volunteers (1994) (2)
HIV-1 Drug Resistance Testing: Health Outcomes Issues (1999) (2)
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles (2022) (2)
O333 Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART) (2008) (2)
Feasibility of testing and detection of HIV-1 drug resistance in proviral DNA (2014) (2)
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
Management of HIV Infection The Potential Role of the Lamivudine/Zidovudine Combination Formulation (1998) (2)
Erratum: Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: A double-blind, placebo-controlled study (AIDS (1994) 8 (641-649)) (1994) (2)
Treatment outcomes amongst previously antiretroviral‐naïve HIV‐infected patients starting lopinavir/ritonavir‐containing antiretroviral regimens at the Royal Free Hospital * (2007) (2)
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles (2022) (2)
Strategies of HIV management — when to switch (2002) (2)
Clinical potential of a new HIV protease inhibitor. (1995) (2)
The use of cyclodextrin solution formulation of itraconazole to treat candidiasis unresponsive to other azole preparations in patients with AIDS (1993) (2)
Clinical staging system for AIDS patients (1995) (1)
Ancillary Benefits of Mycobacterium avium-intracellulare Complex Prophylaxis with Clarithromycin in HIV-Infected Patients (2012) (1)
A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infection. (2001) (1)
P20 Triple protease inhibitor combinations in patients with multidrug resistant HIV infection (2000) (1)
Original article Lack of eYcacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial (1998) (1)
An open-label multicentre pilot study evaluating the pharmacokinetics (PK) of co-administered lopinavir (LPV) and nevirapine (NVP) in HIV+ adults (2008) (1)
AIDS and the British healthcare system. (1997) (1)
Treating neuroendocrine neoplasms in the setting of HIV infection (2021) (1)
Cardiovascular risk assessment in HIV-infected patients attending a designated lipid clinic (2008) (1)
Colorectal 13–21 (2003) (1)
Renal Effects of Intravenous Foscarnet in Hiv Seropositive Patients (1995) (1)
Estimation of the effect of SLCO 1 B 1 polymorphisms on lopinavir plasma concentration in HIV-infected adults (2012) (1)
CYTOMEGALOVIRUS RETINITIS AFTER INITIATION OF HIGHLY ACTIVE ANTIRETROVIRALTHERAPY. AUTHOR'S REPLY (1997) (0)
P14 A preliminary cost analysis of management options for individuals with prior history of CMV disease (2000) (0)
Projects with a strong UK-China-Hong Kong axis devoted to medical care, education and prevention of HIV/Aids (2006) (0)
Kingdom: multicentre cohort study individuals infected with HIV in the United antiretroviral therapy (HAART) among Treatment exhaustion of highly active (2008) (0)
Why HIV antibody testing is unpopular. (1990) (0)
Lack of e Y cacy of low dose oral interferon alfa in symptomatic HIV-1 infection : a randomised , double blind , placebo controlled trial (1998) (0)
Dolutegravir in clinical practice: Uk experience within the named patient programme: P15 (2015) (0)
Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV (2023) (0)
An audit of the viral load of patients from one clinic population on 1st January 2005 to describe the features of those viraemic on ART (2008) (0)
How does HIV / AIDS affect African businesses ? How to treat without the need to deliver continuous HIV suppression ? (2002) (0)
PATHOGENESIS AND IMMUNITY-Kaposi’s Sarcoma-Associated Herpesvirus Cytatoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes (2003) (0)
Clinical outcomes of co-prescription of ranitidine with boosted atazanavir and rilpivirine-based ART (2016) (0)
Drugs in HIV and AIDS (1998) (0)
Autologous K 1 Epitopes Target Darwinian Positively Selected Cytotoxic T Lymphocytes Recognize and Kaposi ' s Sarcoma-Associated Herpesvirus (2003) (0)
Abstracts of the 4th Annual Meeting of the British HIV Association (BHIVA) Held at Keble College, Oxford, 27-29 March 1998 (1998) (0)
Association of risk of toxicity with drug levels of saquinavir when boosted with ritonavir in the MaxCmin1 epsilon t2 trials (2004) (0)
Latent dysbetalipoproteinaemia precipitated by HIV-protease i n h i b i t o rs (1999) (0)
P36 Mechanisms of hyperlipidaemia in HIV patients on multitherapy including protease inhibitors (2000) (0)
The treatment of HIV disease. (1990) (0)
Optimizing indinavir regimens (2000) (0)
Leading article Is interruption of HIV therapy always harmful (2000) (0)
Severe intraocular inflammation after a change of HAART (2000) (0)
P13 Assessing health‐related quality‐of‐life in individuals with HIV/AIDS in the era of HAART (2000) (0)
Dysbetalipoproteinaemia and eruptive xanthomata expressed in an APO-E2, E2 HIV patient on protease inhibitors (1999) (0)
A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults (2008) (0)
High frequency of unexplained breathlessness among UK HIV positive adults (2017) (0)
8 The treatment of HIV disease (1990) (0)
Proceedings of the 7 th Romanian National HIV / AIDS Congress and The 2 nd Central European HIV Forum Sibiu , Romania . 29-31 May 2014 (2014) (0)
Prevalence of lopodystrophy and retinoid syndrome in a 48-week randomized trial to evaluate safety and efficacy of indinavir/ritonavir 800/100 mg versus saquinavir/ritonavir 1000/100 mg: The MaxCmin1 trial (2003) (0)
Selected Topics from the Seventh Conference on Retroviruses and Opportunistic Infections, January 30 - February 2, 2000 (2000) (0)
How to treat without the need to deliver continuous HIV suppression? 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002 - Seattle. (2002) (0)
Population pharmacokinetics (PK) of nevirapine (NVP) in HIV-infected adults (2009) (0)
An achievable goal. (1998) (0)
Conference Report: 6th Retroviruses and Opportunistic Infections, Chicago (1999) (0)
Is Starting First-line Anti-Retroviral Treatment Earlier Cheaper and Cost-effective? (2009) (0)
Book Review: The Guide to Living with HIV Infection: Developed at the Johns Hopkins AIDS Clinic, 6th Edition. By John G. Bartlett and Ann K. Finkbeiner, The Johns Hopkins University Press, 2006, 408 pages. (2008) (0)
HIV care cascade in Albania: analysis of newly diagnosed cases in 2016 (2020) (0)

This paper list is powered by the following services:

Other Resources About Mike Youle

en.wikipedia.org

What Schools Are Affiliated With Mike Youle?

Mike Youle is affiliated with the following schools:

Mike Youle's Academic­Influence.com Rankings